Utilizing selective galactose culturing of GBM cells, we found evidence that HDAC inhibitors in part reduce glioma cell viability through inhibition of glycolysis, indicating that the observed interference with glycolysis is not merely a passenger effect [15]. Here, HDAC9 is linked to central nervous system cancer.